Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury
Key facts
- Who runs it
- University of California, San Francisco
- Where
- Austin, Boston, Charlotte, Cincinnati, Durham, Houston, Indianapolis, Lexington, Madison, Milwaukee, Nashville, Philadelphia, Pittsburgh, Richmond, Salt Lake City, San Francisco, and Seattle, United StatesSee the 18 sites
- Trial code
- Status
- Enrolling by invitation
- Phase
- Phase 2
- People taking part
- 672 people, planned
- Started
- 1 Aug 2024
- Expected to end
- 31 Aug 2029
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Atorvastatin Calcium
- Minocycline Hydrochloride
- Candesartan Cilexetil
- Placebo
- Record updated
- 22 December 2025
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Adults (18-65 years of age, inclusive)
- Presents to a participating enrollment site and is able to receive first dose within 24 hours of non-penetrating head injury warranting clinical evaluation with a non-contrast head CT based on American College of Emergency Physicians (ACEP) Centers for Disease Control and Prevention (CDC) clinical policy for TBI imaging
- Closest, prior to Randomization Glasgow Coma Scale (GCS) score of 9 to 15
- Acute trauma-related neuroimaging abnormality (subarachnoid hemorrhage, contusion, subdural hematoma, petechial hemorrhage, intraventricular hemorrhage) on cranial CT (CT+)
- Initial Glial Fibrillary Acidic Protein (GFAP) blood level >100 pg/ml ≤ 15,000 pg/ml determined using a for Research Use Only (RUO) assay(s) or an Investigation Use Only (IUO) assay(s)
- Persons of childbearing potential (i.e., those not postmenopausal or surgically sterile) may participate provided that they are using adequate birth control methods for the duration of investigational product administration (see manual of procedures for adequate birth control methods)
- Participants able to undergo Magnetic Resonance Imaging (MRI) scans, no contraindications
- Participants or legally authorized representative (LAR) willing and able to provide informed consent
- Participants or LAR able to read, speak, and understand English or Spanish (participating site dependent, where available), including the informed consent form (ICF)
- Willingness and ability to comply with all study procedures, treatment, and follow-up
Who cannot take part
- Currently prescribed one of the investigational products (or other drugs in the same class) prior to injury; or contra-indicated or as listed in the appendices
- Hypersensitivity or intolerance to investigational products or the investigational products' respective classes
- Inability to swallow investigational product capsule
- Pre-existing conditions including disabling developmental, neurologic, psychiatric, medical disorder that continues to produce functional disability up to the time of injury; or imminent death based on clinical judgement
- Unable or unwilling to consume animal byproducts, has a gelatin allergy, and/or religious beliefs that do not permit consuming gelatin
- Renal dysfunction (Creatinine Clearance (CrCl) or estimated Glomerular Filtration Rate (eGFR) (<60 mL/minute/1.73 m2)
- Acute liver disease or hepatic dysfunction (ALT/AST >3 times upper limit of normal lab value)
- Isolated epidural hematoma
- Current enrollment in another interventional study
- Currently pregnant or currently breastfeeding or planning on becoming pregnant in the next 6 months
- Current incarceration or in custody
- Hemodynamic instability, per participating site physician investigator clinical judgment
- Intolerance to small amounts of lactose (less than ½ teaspoonful) daily
- Low likelihood of follow up or study compliance, or any other reason, in the opinion of the participating site investigator, the participants should not participate in the study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- The University of Texas at AustinAustin, United StatesEnrolling by invitation
- Massachusetts General HospitalBoston, United StatesEnrolling by invitation
- Atrium Health Wake Forest BaptistCharlotte, United StatesEnrolling by invitation
- University of Cincinnati Medical CenterCincinnati, United StatesEnrolling by invitation
- Duke University Medical CenterDurham, United StatesEnrolling by invitation
- Baylor College of MedicineHouston, United StatesEnrolling by invitation
- UTHealth HoustonHouston, United StatesEnrolling by invitation
- Indiana University HealthIndianapolis, United StatesEnrolling by invitation
- University of KentuckyLexington, United StatesEnrolling by invitation
- UW Health University HospitalMadison, United StatesEnrolling by invitation
- Medical College of WisconsinMilwaukee, United StatesEnrolling by invitation
- Vanderbilt University Medical CenterNashville, United StatesEnrolling by invitation
- University of PennsylvaniaPhiladelphia, United StatesEnrolling by invitation
- University of PittsburghPittsburgh, United StatesEnrolling by invitation
- Virginia Commonwealth UniversityRichmond, United StatesEnrolling by invitation
- University of UtahSalt Lake City, United StatesEnrolling by invitation
- University of California San FranciscoSan Francisco, United StatesEnrolling by invitation
- University of WashingtonSeattle, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
The purpose of this study is to determine if experimental drug treatment improves recovery after TBI as compared to a control (placebo) group. Changes in recovery will be measured throughout the study. The study drugs listed below are approved by the U.S. Food and Drug Administration (FDA) but are being used "off-label" in this study. This means that the drugs are not currently approved to treat TBI.
The 4 groups in the trial
- Intervention 1: Atorvastatin calcium (ATOR)Existing treatment, for comparison
By Mouth (PO) Twice a day (BID) 80 mg/day, with no loading dose, for 28 days
Treatment: Atorvastatin Calcium
- Intervention 2: Minocycline hydrochloride (MINO)Existing treatment, for comparison
By Mouth (PO) Twice a day (BID) 200 mg loading dose on Day 1, then 100 mg twice daily for 6 days, then placebo twice daily for 21 days
Treatment: Minocycline Hydrochloride
- Intervention 3: Candesartan cilexetil (CAND)Existing treatment, for comparison
By Mouth (PO) Twice a day (BID) 8 mg once on Day 1, then 16 mg daily for 27 days
Treatment: Candesartan Cilexetil
- Matching PlaceboPlacebo, for comparison
By Mouth (PO) Twice a day (BID) 2 capsules 2x/day
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Fit questions
- Built from NCT05826912, who can take part
- Record updated
- 22 December 2025